Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126053061 | 12605306 | 1 | I | 20160411 | 20160512 | 20160729 | 20160729 | PER | US-ALVOGEN-2016-ALVOGEN-024484 | ALVOGEN | 77.00 | YR | F | Y | 51.10000 | KG | 20160729 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126053061 | 12605306 | 1 | PS | DAPSONE. | DAPSONE | 1 | Oral | 205429 | 100 | MG | QD | ||||||||
| 126053061 | 12605306 | 2 | SS | DAPSONE. | DAPSONE | 1 | Oral | 205429 | 100 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126053061 | 12605306 | 1 | Prophylaxis |
| 126053061 | 12605306 | 2 | Pneumonia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126053061 | 12605306 | DE |
| 126053061 | 12605306 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126053061 | 12605306 | Toxic epidermal necrolysis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126053061 | 12605306 | 1 | 20160330 | 20160408 | 0 | |
| 126053061 | 12605306 | 2 | 20160330 | 20160408 | 0 |